1620 Investment Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

1620 Investment Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$36.7K	Buy	+122	New	+$36.8K	0.02%	352

Other funds holding ALNY

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

FAF

Fjarde Ap-fonden Stockholm, Sweden $20.9B AUM 36.93% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Asset Management One Tokyo, Japan $39B AUM 37.51% 1-Year Est. Return

MIF

Mediolanum International Funds Dublin 1, Ireland $11.7B AUM 47.18% 1-Year Est. Return

SSA

Sierra Summit Advisors Incline Village, Nevada $895M AUM 106% 1-Year Est. Return

1620 Investment Advisors's ALNY Position: Q2 2026 in Review

1620 Investment Advisors opened a new position in Alnylam Pharmaceuticals (ALNY) in Q2 2026: 122 shares worth $36.7K. The stake represents 0.02% of the portfolio and ranks #352 among its holdings.

201 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

1620 Investment Advisors held 122 shares of Alnylam Pharmaceuticals worth $36.7K as of Q2 2026.
Alnylam Pharmaceuticals was a new 1620 Investment Advisors position in Q2 2026.
Alnylam Pharmaceuticals made up 0.02% of 1620 Investment Advisors's portfolio in Q2 2026, its #352 holding.
201 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on 1620 Investment Advisors's 13F filing for Q2 2026, filed 14 Jul 2026.